Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT04898907 Not yet recruiting - Healthy Volunteer Clinical Trials

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

Start date: June 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.

NCT ID: NCT04854174 Not yet recruiting - Healthy Volunteers Clinical Trials

A Food Effect Study of ZN-d5 in Healthy Female Volunteers

Start date: June 4, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, sequential, open-label, food effect study to determine the comparative bioavailability of ZN-d5 under fasting and fed conditions, following single-dose oral administration of ZN-d5. The study will be comprised of a pre-study screening, followed by administration of a single dose of ZN-d5 under fasted conditions, a washout period, administration of a single dose of ZN-d5 under fed conditions, and a follow-up period.

NCT ID: NCT04445922 Not yet recruiting - Healthy Volunteers Clinical Trials

Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fed Condition

Start date: July 4, 2020
Phase: Phase 1
Study type: Interventional

An open-label, randomized, two-period, two-group, crossover study was conducted in 26 healthy Chinese volunteers under fed conditions to assess the bioequivalence between two formulations of Anastrozole.

NCT ID: NCT04397471 Not yet recruiting - Clinical trials for Healthy Volunteers for Bone Marrow Donation

A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis

COMET20d
Start date: May 2020
Phase:
Study type: Observational

The COVID-19 pandemic, commonly referred to as "coronavirus", first began in the city of Wuhan, China in December 2019. This virus has since spread globally, with infections reported in nearly every country. COVID-19 targets the body's respiratory system, where infections can be found in the nose, throat and lungs. The effect of COVID-19 infection is very variable, where many people might not know that they have been infected and have recovered from COVID-19. However, COVID-19 infection can cause people to have difficulty breathing. This can be severe enough to require hospitalisation and potentially intensive care treatment. While they are being treated in hospital, COVID-19 infected patients can be found to have inflamed tissue in their lungs (referred to medically as "pneumonitis"). This inflammation is thought to be caused by their body's immune systems overacting to the infection rather than the COVID-19 virus itself. By potentially dampening down this overreaction of their immune system, it is hoped that COVID-19 patients with inflamed lungs have better and quicker chance to survive. Mesenchymal stromal cells (MSCs) have been shown to have anti-inflammatory and healing properties on injured tissue. MSCs have been trialled in various diseases but have not yet been tested on patients with COVID-19. In this study, the investigators will obtain bone marrow from healthy volunteers to develop a cell-based treatment for COVID-19-related pneumonitis. The investigators will also determine whether it is feasible to recruit bone marrow donors in a clinically useful timeframe to treat COVID-19 patients. A future trial, COMET20, will use the bone marrow-derived MSCs (BM-MSCs) manufactured in COMET20d to treat COVID-19 patients suffering with pneumonitis, to determine whether the BMMSCs can reduce the likelihood for mechanical ventilation and reduce hospitalisation.

NCT ID: NCT04006860 Not yet recruiting - Healthy Volunteer Clinical Trials

A Food-Effect Study of SHC014748M in Healthy Subjects

Start date: July 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the effect of food in healthy participants on the bioavailability of SHC014748M Capsules following single dose administration with and without a meal.

NCT ID: NCT03988673 Not yet recruiting - Healthy Volunteers Clinical Trials

Comparison of Explicit, Implicit and no Values Clarification Decision Aids for Men Considering Prostate Cancer Screening

Start date: September 2019
Phase: N/A
Study type: Interventional

The investigators aim at comparing the perceived clarity of personal values in men considering PSA screening using decision aids with no VCM versus an implicit VCM versus an explicit VCM. This study will add to the body of evidence on the role of decision aids to support health preference-sensitive choices and provide further insight on the impact of different methods for eliciting people's values embedded within a decision aid.

NCT ID: NCT03973632 Not yet recruiting - Healthy Volunteer Clinical Trials

Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions

Start date: July 2019
Phase: Phase 1
Study type: Interventional

To evaluate the food-effect of SH-1028 Tablets by pharmacokinetics in healthy subjects under fasting and fed conditions.

NCT ID: NCT03931369 Not yet recruiting - Healthy Volunteers Clinical Trials

Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)

TOLVATHIRST
Start date: September 6, 2019
Phase: Phase 2
Study type: Interventional

Tolvaptan is a new drug that specifically antagonizes the V2-receptor of antidiuretic hormone (ADH) and leads to water diuresis: During acute administration of tolvaptan, the main fear is to induce a too fast increase in plasma sodium concentration and in turn brain damageHowever, the tolvaptan-induced increase in plasma sodium concentration is expected to stimulate thirst, preventing major negative water balance. The investigators hypothesize that tolvaptan-induced increase in plasma osmolality (and sodium concentration) is dependent of thirst adaptation that is influenced by physiological factors, namely age and sex. To address the effect of a single oral administration of tolvaptan at a dosage used during hyponatremia (15 mg) under free water access in healthy volunteers. Primary outcome will be the maximal change in serum sodium concentration within the 6 hours following tolvaptan administration.

NCT ID: NCT03852277 Not yet recruiting - Healthy Volunteers Clinical Trials

A Study to Assess Safety, Tolerability, Pharmacodynamics, Immunogenicity, Exploratory Clinical Efficacy, and Pharmacokinetics of Intravenous Infusions of E2814 in Healthy Participants and Participants With Prodromal Alzheimer's Disease (AD) to Moderate AD With and Without Detectable Tau Pathology

Start date: February 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of the study is to evaluate the safety and tolerability of single and multiple ascending doses in healthy participants and participants with prodromal to moderate AD, respectively, and to demonstrate slowing in progression of tau pathology in the brain as determined by tau-positron emission tomography (PET) in participants with prodromal to moderate AD.

NCT ID: NCT03422055 Not yet recruiting - Healthy Volunteer Clinical Trials

Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m

NANO-ATHERO
Start date: February 2018
Phase: Phase 1
Study type: Interventional

The development of an innovative imaging agent capable of non-invasively detecting vulnerable plaques is a major objective of research in cardiovascular pathology. Such a tool would allow for better identification of patients at risk of acute events. We showed that 99mTechnetium (99mTc)-labeled fucoidan was able to target P-selectine expressed by activated platelets in vitro in humans and in vivo in a model of abdominal aortic aorta thrombus and endocarditic vegetations in rats. One of the objectives of the Nanoathero program is the clinical translation of the 99mTc-fucoidan. As a first step, we will assess the safety, biodistribution and dosimetry of this new radiopharmaceutical in humans.